Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: Results from OPUS-TIMI 16 and TACTICS-TIMI 18

American Heart Journal

Volumn 148, Issue 1, 2004, Pages 173-180

  Wylie, John V ^a,d   Murphy, Sabina A ^b   Morrow, David A ^b   De Lemos, James A ^c   Antman, Elliott M ^b   Cannon, Christopher P ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; ELECTROCARDIOGRAPHY MONITORING; HEART INFARCTION; HEART RATE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; VALIDATION PROCESS;

AGED; ANGINA, UNSTABLE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 3142579184     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.12.018     Document Type: Article

References (33)

1. Boersma E., Pieper K.S., Steyerberg E.W., et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 101:2000;2557-2567
2. Holmes D.R. Jr, Berger P.B., Hochman J.S., et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation. 100:1999;2067-2073
3. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002 summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 106:2002;1893-1900
4. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI a method for prognostication and therapeutic decision making. JAMA. 284:2000;835-842
5. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 36:2000;970-1062
6. Aronow W.S., Ahn C., Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 88:2001;1298-1300
7. Vantrimpont P., Rouleau J.L., Wun C.C., et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. SAVE Investigators. J Am Coll Cardiol. 29:1997;229-236
8. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 327:1992;669-677
9. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:2003;1309-1321
10. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 349:2003;1893-1906
11. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 102:2000;149-156
12. Killip T. III, Kimball J.T. Treatment of myocardial infarction in a coronary care unit a two-year experience with 250 patients. Am J Cardiol. 20:1967;457-464
13. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:2001;1014-1021
14. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:1982;29-36
15. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 344:2001;1879-1887
16. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41:2003;1264-1272
17. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST-elevation myocardial infarction a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 102:2000;2031-2037
18. O'Connor C.M., Hathaway W.R., Bates E.R., et al. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction development of a predictive model. Am Heart J. 133:1997;663-673
19. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167
20. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:2001;379-385
21. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 108:2003;275-281
22. Schocken D.D., Arrieta M.I., Leaverton P.E., et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 20:1992;301-306
23. Jacobs D.R. Jr, Kroenke C., Crow R., et al. PREDICT a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation. 100:1999;599-607
24. Spencer F.A., Meyer T.E., Gore J.M., et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure the National Registry of Myocardial Infarction. Circulation. 105:2002;2605-2610
25. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women NHANES I epidemiologic follow-up study. Arch Intern Med. 161:2001;996-1002
26. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 102:2000;1014-1019
27. Lewis E.F., Moye L.A., Rouleau J.L., et al. Predictors of late development of heart failure in stable survivors of myocardial infarction the CARE study. J Am Coll Cardiol. 42:2003;1446-1453
28. Lee K.L., Woodlief L.H., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction results from an international trial of 41, 021 patients. GUSTO-I Investigators. Circulation. 91:1995;1659-1668
29. Disegni E., Goldbourt U., Reicher-Reiss H., et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol. 48:1995;1197-1205
30. Lindahl B., Venge P., Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation. 93:1996;1651-1657
31. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 335:1996;1342-1349
32. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
33. Berger C.J., Murabito J.M., Evans J.C., et al. Prognosis after first myocardial infarction comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA. 268:1992;1545-1551